ALPN 101

Drug Profile

ALPN 101

Alternative Names: ALPN 101; CD28/ICOS antagonist - Alpine; ICOS/CD28 antagonist - Alpine

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alpine Immune Sciences
  • Class Immunotherapies; Proteins
  • Mechanism of Action CD28 antigen inhibitors; Immunosuppressants; Inducible T-cell co-stimulator protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 28 Mar 2018 Alpine Immune Sciences announces intention to submit IND to US FDA for Inflammation and Autoimmune disorders in fourth quarter of 2018
  • 09 Dec 2017 Pharmacodynamics data from a preclinical study in Inflammation and Autoimmune disorders released by Alpine Immune Sciences
  • 06 Nov 2017 Pharmacodynamic results from a preclinical study in Inflammation and Autoimmune disorders released by Alpine Immune Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top